Curcumin-loaded nanostructured lipid carriers prepared using Peceol™ and olive oil in photodynamic therapy: development and application in breast cancer cell line.


Journal

International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847

Informations de publication

Date de publication:
2019
Historique:
received: 07 04 2019
accepted: 04 06 2019
entrez: 3 8 2019
pubmed: 3 8 2019
medline: 29 9 2019
Statut: epublish

Résumé

To potentiate the anticancer activity of curcumin (CUR) by improving its cell penetration potentials through formulating it into nanostructured lipid carriers (NLCs) and using the prepared NLCs in photodynamic therapy. A 3×4 factorial design was used to obtain 12 CUR-NLCs using two factors on different levels: (1) the solid lipid type at four levels and (2) the solid to liquid lipid ratio at three levels. Olive oil, Tween 80 and lecithin were chosen as liquid lipid, surfactant and co-surfactant, respectively. CUR-NLCs prepared by high shear hot homogenization method were evaluated by determination of particle size (PS), polydispersity index, zeta potential (ZP), entrapment efficiency percent, drug loading percent and in vitro drug release. Optimization was based on the evaluation results using response surface modeling (RSM). Optimized formulae were tested for their in vitro release pattern and for dark and photo-cytotoxic anticancer activity on breast cancer cell line in comparison to free CUR. Evaluation tests showed the appropriateness of NLCs prepared from glyceryl monooleate and Geleol™ helped choosing two optimized formulae, PE3 and GE3. PE3 (prepared using glyceryl monooleate) showed enhanced release rates compared to GE3 (prepared from Geleol) and superior cytotoxic anticancer activity compared to both GE3 and free CUR under both light and dark conditions. The small mean PS, spherical shape as well as the negative ZP enhanced the internalization of the NLCs within cells. Modulation and inhibition of P-glycoprotein expression by glyceryl monooleate synergized the cytotoxic activity of CUR. CUR loading in NLCs enhanced its cell penetration and cytotoxic anticancer properties both in dark and in light conditions.

Identifiants

pubmed: 31371948
doi: 10.2147/IJN.S210484
pii: 210484
pmc: PMC6636435
doi:

Substances chimiques

Drug Carriers 0
Lipids 0
Oleic Acids 0
Olive Oil 0
Peceol 0
Curcumin IT942ZTH98

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5073-5085

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

Eur J Pharm Biopharm. 2000 Jul;50(1):161-77
pubmed: 10840199
Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96
pubmed: 11311991
FEBS Lett. 2002 Feb 13;512(1-3):334-40
pubmed: 11852106
Adv Drug Deliv Rev. 2002 Nov 1;54 Suppl 1:S131-55
pubmed: 12460720
Int J Pharm. 2003 Jul 9;260(1):47-57
pubmed: 12818809
Int J Pharm. 2004 Jun 18;278(1):71-7
pubmed: 15158950
J Environ Pathol Toxicol Oncol. 2006;25(1-2):205-15
pubmed: 16566718
Pharmazie. 2006 May;61(5):375-86
pubmed: 16724531
J Pharm Pharm Sci. 2007;10(3):319-31
pubmed: 17727795
Biochem Pharmacol. 2008 Feb 15;75(4):787-809
pubmed: 17900536
Small. 2010 Jan;6(1):12-21
pubmed: 19844908
Phytomedicine. 2010 Jun;17(7):506-12
pubmed: 19879740
AAPS PharmSciTech. 2011 Mar;12(1):62-76
pubmed: 21174180
Int J Oncol. 2012 Dec;41(6):2184-90
pubmed: 23064512
J Agric Food Chem. 2013 Feb 27;61(8):1878-83
pubmed: 23362941
Biomaterials. 2014 Mar;35(10):3365-83
pubmed: 24439402
Adv Pharm Bull. 2014;4(3):219-24
pubmed: 24754004
Expert Opin Drug Deliv. 2014 Aug;11(8):1183-201
pubmed: 24857605
J Cancer Epidemiol. 2014;2014:437971
pubmed: 25328522
Drug Deliv. 2016 May;23(4):1326-34
pubmed: 25367836
ScientificWorldJournal. 2015;2015:541510
pubmed: 25861680
Nanomedicine. 2016 Jan;12(1):143-61
pubmed: 26410277
J Control Release. 2016 Mar 10;225:1-30
pubmed: 26778694
Molecules. 2016 Mar 11;21(3):342
pubmed: 26978341
Anticancer Res. 2016 Jul;36(7):3363-72
pubmed: 27354595
Adv Pharm Bull. 2016 Jun;6(2):143-51
pubmed: 27478775
Drug Des Devel Ther. 2016 Aug 02;10:2467-75
pubmed: 27536067
Photodiagnosis Photodyn Ther. 2017 Jun;18:284-294
pubmed: 28300724
Int J Nanomedicine. 2017 Apr 19;12:3253-3265
pubmed: 28458544
Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1471-1482
pubmed: 28884598
Pharm Dev Technol. 2018 Jan;23(1):96-105
pubmed: 28949267
Drug Dev Ind Pharm. 2018 Nov;44(11):1809-1816
pubmed: 29969300
J Control Release. 2018 Nov 28;290:165-179
pubmed: 30142410
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Biochim Biophys Acta. 1995 Feb 15;1233(2):134-44
pubmed: 7865538

Auteurs

Amr Ehab Kamel (AE)

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy and Drug Technology, Heliopolis University, Cairo, Egypt.

Maha Fadel (M)

Pharmaceutical Nano-Technology Lab., Medical Applications of Laser Department, Niles, Cairo University, Cairo, Egypt.

Dina Louis (D)

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy and Drug Technology, Heliopolis University, Cairo, Egypt.
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH